NCT06592625尚未招募2 期
A Multicenter, Single-arm, Phase 2 Study of Neoadjuvant SHR-A1811 Plus Adebrelimab Injection for Early-stage or Locally Advanced HR Negative or Low Expression/HER2 Low Expression Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Investigator-assessed tpCR
研究概览
简要总结
The study is being conducted to evaluate the preliminary efficacy, safety, and pharmacokinetic characteristics of the combination of SHR-A1811 with Adebrelimab Injection in treatment-naive patients with early-stage or locally advanced HR-negative or low expression, HER2 low expression breast cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female treatment-naïve patients aged ≥18 years and ≤75 years.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-
- •Breast cancer meeting the following criteria:
- •Histologically confirmed invasive breast cancer with at least one tumor lesion >2 cm in diameter.
- •Clinical stage II or III.
- •Histologically or cytologically confirmed HR-negative or low expression and HER2 low expression breast cancer.
- •Adequate major organ function.
- •Females of childbearing potential must agree to use highly effective contraception methods and avoid egg donation, and must have a negative serum pregnancy test within 7 days prior to the first treatment and during the study period. They must not be breastfeeding.
- •Voluntarily agrees to participate in the clinical study and signs the informed consent form.
排除标准
- •Tumor-related medical history and treatment history:
- •Bilateral breast cancer (including contralateral carcinoma in situ).
- •Stage IV (metastatic) breast cancer.
- •Inflammatory breast cancer.
- •Diagnosis of ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS) within 5 years.
- •History of invasive breast cancer or metastatic breast cancer.
- •Prior surgical resection of the breast primary lesion or axillary lymph nodes before signing the informed consent.
- •Diagnosis of any malignancy within 5 years before signing the informed consent, excluding adequately treated cervical carcinoma in situ, cutaneous basal cell carcinoma or squamous cellcancer.
- •Previous systemic targeted therapy, endocrine therapy, radiotherapy, or immunotherapy for any malignancy.
- •Any of the following comorbidities/ medical history or treatment history:
- •Known or suspected interstitial pneumonia; moderate to severe pulmonary disease significantly affecting respiratory function within three months before the first dose that could interfere with the detection or management of drug-related pulmonary toxicity; any pulmonary involvement from autoimmune, connective tissue, or inflammatory diseases, or previous total lung resection.
- •Severe cardiovascular disease.
- •Investigator determines any of the following:
- •QT interval corrected by Fridericia's formula (QTcF) > 470 msec during screening.
- •History of prolonged QT interval.
- •Congenital long QT syndrome or family history of long QT syndrome.
- •Human Immunodeficiency Virus (HIV) infection or known Acquired Immunodeficiency Syndrome (AIDS), active tuberculosis, active hepatitis B, hepatitis C, or concurrent hepatitis B and C infections.
- •Vascular thrombotic event within 3 months before randomization, such as deep vein thrombosis or pulmonary embolism.
- •Severe infection within 4 weeks before randomization, or fever > 38.5°C of unknown cause during screening or before the first dose.
- •Clinically significant bleeding symptoms or a known tendency to bleed within 1 month before signing the informed consent; known genetic or acquired bleeding or thrombotic tendencies.
- •Abnormal coagulation function, bleeding tendency, or ongoing anticoagulant therapy with thrombolytics or long-term anticoagulation with warfarin or heparin, or long-term antiplatelet therapy.
- •Other conditions that make the patient unsuitable for the study, such as severe systemic disease, kidney transplant, active bleeding disorders, or serious chronic gastrointestinal diseases related to diarrhea.
- •Meets any of the following criteria related to study treatment:
- •Systemic immunostimulatory agent treatment within 4 weeks before the first dose.
- •Systemic immunosuppressive agent treatment within 4 weeks before the first dose. Excludes intranasal and inhaled corticosteroids or physiological doses of systemic steroids.
- •Known allergy to the investigational product or any of its excipients.
- •Participation in other anticancer therapy clinical trials concurrently.
- •Received live attenuated vaccines within 30 days before the first dose of the study intervention.
- •Previous or planned allogeneic bone marrow transplantation or solid organ transplantation.
- •Women who have given birth within 1 year or are currently breastfeeding.
- •Known history of substance abuse, alcoholism, or drug addiction.
- •Other serious physical or mental illnesses or abnormal laboratory test results that may increase the risk of participating in the study or interfere with the study results, as determined by the investigator.
研究组 & 干预措施
SHR-A1811 plus Adebrelimab
Experimental
干预措施: SHR-A1811 (Drug)
SHR-A1811 plus Adebrelimab
Experimental
干预措施: Adebrelimab (Drug)
结局指标
主要结局
Investigator-assessed tpCR
时间窗: Approximately 18 weeks after the first dose (after breast cancer surgery
次要结局
- Objective Response Rate (ORR)(Approximately 18 weeks after the first dose (before breast cancer surgery))
- Change in Ki-67 index(Approximately 18 weeks after the first dose (after breast cancer surgery))
- Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0)(From signing the informed consent form to 40 days after the last dose of SHR-A1811, or 90 days after the last dose of Adebrelimab Injection (whichever is later))
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Pre-operative chemotherapy associated or not with zoledronate and atorvastatin in patients with triple negative breast cancer - YAPPETIZER StudyTriple Negative Breast CancerMedDRA version: 20.0Level: PTClassification code 10075566Term: Triple negative breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-005112-17-ITIRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI154
已完成
1 期
A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin LymphomaRelapsed or Refractory Hodgkin LymphomaNCT01572519Janssen Research & Development, LLC21
Unknown
2 期
Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic CancerBorderline Resectable Pancreatic CancerNCT03850769Peking Union Medical College Hospital60
招募中
2 期
A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)Relapsed or Refractory Acute Myeloid Leukemia (AML)NCT05241093Tarapeutics Science Inc.18
撤回
2 期
Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast CancerBreast CancerNCT02215876Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins